Rong-Ji Mu
Overview
Explore the profile of Rong-Ji Mu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang N, Huang X, Jiang X, Wang L, Cheng S, Xu P, et al.
Hematol Oncol
. 2024 Dec;
43(1):e70012.
PMID: 39716437
Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron...
2.
Wang Y, Shi Q, Shi Z, Tian S, Zhang M, Shen R, et al.
Blood Adv
. 2024 Jan;
8(7):1587-1599.
PMID: 38170757
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive subtype of lymphoma with clinical and biological heterogeneity. The International Prognostic Index (IPI) shows great prognostic capability in the era of...
3.
Zhang M, Tian S, Fu D, Wang L, Cheng S, Yi H, et al.
Cancer Cell
. 2023 Sep;
41(10):1705-1716.e5.
PMID: 37774697
We report the results of GUIDANCE-01 (NCT04025593), a randomized, phase II trial of R-CHOP alone or combined with targeted agents (R-CHOP-X) guided by genetic subtyping of newly diagnosed, intermediate-risk, or...
4.
Shi Q, He Y, Yi H, Mu R, Jiang X, Fu D, et al.
Cancer Commun (Lond)
. 2023 Jul;
43(8):896-908.
PMID: 37403255
Background: The current standard of care for non-bulky diffuse large B-cell lymphoma (DLBCL) patients with an International Prognostic Index (IPI) of 0 is four cycles of rituximab plus cyclophosphamide, doxorubicin,...